Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2025 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Robert Blum - Investor Relations, Lytham Partners Josh Disbrow - Chief Executive Officer Ryan Selhorn - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Operator Good day, everyone, and welcome to the Aytu BioPharma Fiscal 2025 Q2 Earnings Call. At this time, all participants have been placed on a listen-only. [Operator Instructions] It is now my pleasure to turn ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ___________ Commission File Number: 001-38247 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) | Delaware | 47-0883144 | | -- ...

Exhibit 99.1 Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results Net income of $0.8 million Adjusted EBITDA1 of $1.3 million Pediatric Portfolio net revenue up 86% sequentially First quarterly sequential prescription increase for both ADHD and Pediatric portfolios since Q2 fiscal 2023 $20.4 million cash balance at December 31, 2024 Company to host conference call and webcast today, February 12, 2025, at 4:30 p.m. Eastern time Consumer Health – Discontinued Operations DENVER, ...

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2025 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Robert Blum - IR, Lytham Partners Josh Disbrow - Chief Executive Officer Mark Oki - Outgoing Chief Financial Officer Ryan Selhorn - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Operator Greetings. Welcome to the Aytu BioPharma Fiscal 2025 Q1 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ___________ Commission File Number: 001-38247 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) (Address of principal executi ...

Financial Performance - Net income for Q1 fiscal 2025 was $1.5 million, or $0.24 net income per share basic, compared to a net loss of $8.1 million in Q1 fiscal 2024[16]. - Total net revenue for Q1 fiscal 2025 was $16.6 million, a decrease from $17.8 million in the prior year period, primarily due to changes in payor coverage[12]. - Net revenue for the three months ended September 30, 2024, was $16,574,000, a decrease of 7% from $17,817,000 for the same period in 2023[23]. - The company reported a net income of $1,474,000 for the three months ended September 30, 2024, compared to a net loss of $8,120,000 for the same period in 2023[23]. - Aytu BioPharma reported a net loss of $4,617,000 for the three months ended June 30, 2024, compared to a net loss of $2,887,000 for the previous quarter[27]. - Aytu BioPharma's total net loss for the twelve months ended June 30, 2024, was $15,844,000[27]. Revenue and Market Performance - ADHD Portfolio net revenue increased 1% to $15.3 million in Q1 fiscal 2025, while Pediatric Portfolio net revenue increased 54% sequentially to $1.3 million[2]. - Approximately 99,000 ADHD prescriptions were written in Q1 fiscal 2025, compared to 90,000 in Q1 2023, indicating a recovery in the ADHD market[3]. Expenses and Cost Management - Adjusted EBITDA for Q1 fiscal 2025 was $1.9 million, down from $2.4 million in Q1 fiscal 2024[17]. - Operating expenses, excluding amortization and restructuring costs, were $11.2 million in Q1 fiscal 2025, down from $13.0 million in the prior year period[14]. - Total operating expenses decreased to $12,915,000 from $13,905,000, primarily due to reductions in selling and marketing expenses[23]. - The company implemented an organizational optimization plan expected to reduce operating expenses by at least $2.0 million annually[4]. - The company is focusing on restructuring costs, which amounted to $784,000 for the three months ended September 30, 2024, as part of its strategic initiatives[23]. Cash and Assets - Cash and cash equivalents were $20.1 million at September 30, 2024, compared to $20.0 million at June 30, 2024[17]. - Cash and cash equivalents as of September 30, 2024, were $20,108,000, slightly up from $20,006,000 as of June 30, 2024[24]. - Total assets decreased to $115,831,000 from $118,095,000, indicating a reduction in the company's asset base[24]. - Current liabilities increased to $61,252,000 from $62,228,000, reflecting changes in accounts payable and accrued liabilities[24]. Profitability Metrics - Gross profit percentage was 72% in Q1 fiscal 2025, down from 73% in Q1 fiscal 2024[2]. - Gross profit for the same period was $11,985,000, down from $13,038,000, reflecting a gross margin decrease[23]. - Adjusted EBITDA for the three months ended September 30, 2024, was $1,931,000, down from $2,415,000 in the same period last year[25]. Other Financial Metrics - Interest expense for the quarter was $1,253,000, slightly down from $1,266,000 in the previous quarter[27]. - The company incurred restructuring costs of $1,912,000 during the quarter, indicating ongoing operational adjustments[27]. - Pipeline research and development costs amounted to $599,000, reflecting continued investment in new product development[27]. - Total income tax expense for the quarter was $695,000, up from $245,000 in the previous quarter[27]. - Stock-based compensation expense was $243,000, a decrease from $699,000 in the previous quarter[27]. - The company reported a gain of $1,463,000 from derivative warrant liabilities, a significant improvement from a loss of $1,017,000 in the previous quarter[27]. Strategic Initiatives - The company successfully completed the wind down and divestiture of its Consumer Health business, marking the end of its restructuring efforts[9].

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q4 2024 Results Conference Call September 26, 2024 4:30 PM ET Company Participants Robert Blum - IR, Lytham Partners Josh Disbrow - Chief Executive Officer Mark Oki - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Operator Greetings, welcome to the Aytu BioPharma's Fiscal 2024 Q4 Earnings Call. At this time, all participants have been placed on a listen-only mode. [Operator Instructions] Please note this conference is being recorded. I will n ...

Exhibit 99.1 Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results Full year fiscal 2024 consolidated net revenue of $81.0 million; Rx Segment net revenue of $65.2 million Full year fiscal 2024 ADHD Portfolio net revenue up 23% compared to fiscal 2023 Full year fiscal 2024 adjusted EBITDA1 improved to $9.2 million, up by $5.7 million compared to fiscal 2023 $20.0 million cash balance at June 30, 2024 Company expects Rx Segment net revenue and adjusted EBITDA growt ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-38247 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Common Stock, par value $0.0001 per share AYTU The Nasdaq Capital Market Securities registered pursu ...

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q3 2024 Earnings Call Transcript May 15, 2024 4:30 PM ET Company Participants Roger Weiss - Investor Relations Joshua Disbrow - Chief Executive Officer Mark Oki - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Jennifer Kim - Cantor Fitzgerald Operator Good afternoon, everyone and welcome to the Aytu BioPharma Fiscal 2024 Third Quarter Earnings Call. At this time, all participants have been placed on a listen-only mode. [Operator Instructions] ...